Harissa H. Hasbullah

Kuala Lumpur, MY 
Kuala Lumpur, MY 

Overview

Harissa Hasbullah practices practicing medicine in Kuala Lumpur, Malaysia.

Their clinical expertise encompasses Breast Cancer in Men, Nasopharyngeal Carcinoma, Mononucleosis, and Lung Metastases.

They are actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 1 clinical trial.

Locations

Kuala Lumpur, Malaysia
Other Locations
Sungai Buloh, Malaysia
Kuala Selangor, Malaysia
Kota Bharu, Malaysia
Shah Alam, Malaysia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3

12 Total Publications

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 27, 2023

Frequently Asked Questions about Harissa H. Hasbullah

Is Harissa H. Hasbullah a top-rated expert for Breast Cancer in Men?

MediFind is an objective health platform that identifies experts based on real-world data. Harissa H. Hasbullah is classified as an Experienced expert for Breast Cancer in Men, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Harissa H. Hasbullah participate in research or clinical trials?

Yes. Harissa H. Hasbullah has published 12 articles and abstracts on conditions like Breast Cancer in Men. You can view a list of Harissa H. Hasbullah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hasbullah's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile